VERICEL CORP (VCEL) Stock Overview
USA - NASDAQ:VCEL - US92346J1088 - Common Stock
VCEL Key Statistics, Chart & Performance
The current stock price of VCEL is 36.45 USD. In the past month the price increased by 17.03%. In the past year, price decreased by -16.28%.
VCEL Latest News, Press Relases and Analysis
VCEL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.44 | 401.13B | ||
| AMGN | AMGEN INC | 13.38 | 157.12B | ||
| GILD | GILEAD SCIENCES INC | 15.34 | 147.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.7 | 107.28B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.49 | 69.14B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 61.87B | ||
| ARGX | ARGENX SE - ADR | 90.72 | 51.44B | ||
| INSM | INSMED INC | N/A | 35.13B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.11 | 34.82B | ||
| NTRA | NATERA INC | N/A | 26.54B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.40B | ||
| BIIB | BIOGEN INC | 9.31 | 21.86B |
Related stock screener links
About VCEL
Company Profile
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 357 full-time employees. The firm is a provider of advanced therapies for the sports medicine and severe burn care markets. The company markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full-thickness burns greater than or equal to 30% of total body surface area. The firm also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adult and pediatric patients with deep partial thickness and/or full-thickness thermal burns.
Company Info
VERICEL CORP
64 Sidney St
Cambridge MASSACHUSETTS 02139 US
CEO: Dominick C. Colangelo
Employees: 357
Phone: 17349305555
VERICEL CORP / VCEL FAQ
What does VERICEL CORP do?
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 357 full-time employees. The firm is a provider of advanced therapies for the sports medicine and severe burn care markets. The company markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full-thickness burns greater than or equal to 30% of total body surface area. The firm also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adult and pediatric patients with deep partial thickness and/or full-thickness thermal burns.
What is the stock price of VERICEL CORP today?
The current stock price of VCEL is 36.45 USD. The price decreased by -1.03% in the last trading session.
What is the dividend status of VERICEL CORP?
VCEL does not pay a dividend.
What is the ChartMill technical and fundamental rating of VCEL stock?
VCEL has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What sector and industry does VERICEL CORP belong to?
VERICEL CORP (VCEL) operates in the Health Care sector and the Biotechnology industry.
Can you provide the upcoming earnings date for VERICEL CORP?
VERICEL CORP (VCEL) will report earnings on 2025-11-06, before the market open.
VCEL Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to VCEL. When comparing the yearly performance of all stocks, VCEL is a bad performer in the overall market: 79.86% of all stocks are doing better.
VCEL Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to VCEL. VCEL scores excellent on profitability, but there are some minor concerns on its financial health.
VCEL Financial Highlights
Over the last trailing twelve months VCEL reported a non-GAAP Earnings per Share(EPS) of 0.12. The EPS increased by 864691128455134800% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 2.85% | ||
| ROA | 1.63% | ||
| ROE | 2.32% | ||
| Debt/Equity | 0.01 |
VCEL Forecast & Estimates
14 analysts have analysed VCEL and the average price target is 55.42 USD. This implies a price increase of 52.04% is expected in the next year compared to the current price of 36.45.
For the next year, analysts expect an EPS growth of 24.67% and a revenue growth 15.49% for VCEL